A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
PHASE3
This study will assess the safety and efficacy of ixekizumab (LY2439821), c...
Status
Completed
Location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
PHASE2
The primary objective of this study is to evaluate the efficacy of andecali...